Glucan-encapsulated siRNA for treating type 2 diabetes mellitus

US10077446B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US
• University of Massachusetts · US

Inventors

• George Kunos · Bethesda, US
• Tony Jourdan · Rockville, US
• Michael P. Czech · Frankfurt am Main, DE
• Myriam Aouadi · Worcester, US

Key dates

• Filing date: Jun 24, 2014
• Grant date: Sep 18, 2018
• Expiry date: Jun 24, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor.